An interventional study of Acupuncture and Sham acupuncture in Sudden Sensorineural Hearing Loss (SSNHL), sponsored by Eye & ENT Hospital of Fudan University. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-08.
Sponsored by Eye & ENT Hospital of Fudan University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Hearing Loss, Sudden with a site in China — 11 open to participants now, 11 under way, 1 of them phase 3. Hearing Loss, Sudden · China.
Among the 18 studies in Hearing Loss, Sudden with a site in China, this one has the largest planned enrollment of the 15 interventional ones that give a count, is one of 5 that started in 2026, is one of 7 with no phase, reaches primary completion later than 6 of the 10 other live ones, and was the 16th registered.
66 studies on the registry are indexed under Hearing Loss, Sudden; 25 are open to participants now.
Browse Hearing Loss, Sudden studies →11 of the 18 studies in Hearing Loss, Sudden with a site in China are open now. Recruiting first, the newest first:
Guangdong Provincial People's Hospital · Sites in China
Ages 18–60
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–60
Beijing Tsinghua Chang Gung Hospital · Sites in China
Ages 18–70
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–65 · Healthy volunteers
Eye & ENT Hospital of Fudan University · Sites in China
Ages 12–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 10 Hearing Loss, Sudden studies recruiting now, 3 (30%) set no upper age limit and 5 (50%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 1 · Phase 4 1
First in 2019; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 256 is above the median of 72 across 49 interventional studies indexed under Hearing Loss, Sudden.
Median enrollment 90 across the 15 interventional studies, 90 across the 3 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 18 have an industry lead sponsor. The 10 most frequent:
Eye & ENT Hospital of Fudan University is the lead sponsor of 127 studies on the registry; 71 are open to participants now.
Eye & ENT Hospital of Fudan University has 6 studies filed under Hearing Loss, Sudden — fewer than ten, so there is no comparison to draw.
2 of the studies in Hearing Loss, Sudden with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07134075Eye & ENT Hospital of Fudan UniversityIntracochlear Injection of Glucocorticoid | 2027-08-01 |
| NCT07505667Guangdong Provincial People's HospitalYiyuancong for the Treatment of Sudden Sensorineural Hearing Loss | 2027-11-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Hearing Loss, Sudden with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this multicenter, prospective, randomized controlled trial is to evaluate the efficacy and safety of acupuncture combined with corticosteroid therapy in treating sudden sensorineural hearing loss (SSNHL). The main questions it aims to answer are:
Does acupuncture combined with corticosteroids improve hearing recovery (pure tone audiometry, PTA) at 8 weeks compared with sham acupuncture combined with corticosteroids? Does this treatment improve secondary outcomes, including tinnitus, dizziness, sleep quality, anxiety, and quality of life? Researchers will compare acupuncture (experimental group) with sham acupuncture (control group) to determine the added therapeutic effect of acupuncture.
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will receive real acupuncture 3 times per week for 4 weeks, together with oral prednisone (1 mg/kg/day, maximum 60 mg/day) for 7 days followed by a 7-day taper, plus oral Ginkgo biloba extract for 4 weeks.
Procedure: Acupuncture
Participants in this group will receive sham acupuncture (applied to the same acupoint locations as in the experimental group, while the needle tip does not penetrate the skin) 3 times per week for 4 weeks, together with oral prednisone (1 mg/kg/day, maximum 60 mg/day) for 7 days followed by a 7-day taper, plus oral Ginkgo biloba extract for 4 weeks.
Procedure: Sham acupuncture
Main Acupoints (Fixed): Tinghui (GB2), Yifeng (SJ17), Tinggong (SI19), and Shuaigu (GB8) on the affected side; Baihui (GV20) at the vertex; Zhongzhu (SJ3) and Zulinqi (GB41) bilaterally. Adjunct Acupoints (Bilateral, selected based on TCM pattern differentiation): External Pathogen Invasion: Hegu (LI4) + Waiguan (SJ5) Liver Fire Harassing Upper: Yanglingquan (GB34) + Xingjian (LR2) Phlegm Fire Stagnation: Fenglong (ST40) + Neiting (ST44) Qi Stagnation and Blood Stasis: Xuehai (SP10) + Taichong (LR3) Kidney Essence Deficiency: Taixi (KI3) + Sanyinjiao (SP6) Spleen and Stomach Deficiency: Zusanli (ST36) + Qihai (CV6)
The same acupoints are used, but with blunt-tip placebo needles that do not penetrate the skin. The needles are fixed with adhesive patches, and the procedure is identical to the real acupuncture group to maintain blinding.
Hearing improvement
Hearing improvement measured by the change in Pure Tone Audiometry (PTA) average (500, 1000, 2000, and 4000 Hz) from baseline to week 8, compared between the acupuncture + corticosteroid group and the sham acupuncture + corticosteroid group.
Time frame: Week 8
Hearing outcomes at multiple time points
Changes in PTA at weeks 1, 2, 4, 8, and 12
Time frame: week 1, 2, 4, 8, and 12
Word Recognition Score (WRS)
Changes of WRS from baseline at weeks 1, 2, 4, 8, and 12
Time frame: weeks 1, 2, 4, 8, and 12
Sudden hearing loss recovery grade
Complete, significant, partial, or no recovery according to the 2019 AAO-HNS guideline criteria
Time frame: weeks 1, 2, 4, 8, and 12
TCM symptom score
Change from baseline to week 8 using the pattern-specific TCM symptom scale
Time frame: week 8
Sensory Organization Test
Sensory Organization Test (SOT) scores at weeks 1, 2, 4, 8, and 12
Time frame: weeks 1, 2, 4, 8, and 12
Insomnia Severity Index (ISI)
Changes from baseline at weeks 1, 2, 4, 8, and 12
Time frame: weeks 1, 2, 4, 8, and 12
Dizziness Handicap Inventory (DHI)
Changes from baseline at weeks 1, 2, 4, 8, and 12
Time frame: weeks 1, 2, 4, 8, and 12
Tinnitus Handicap Inventory (THI)
Changes from baseline at weeks 1, 2, 4, 8, and 12
Time frame: weeks 1, 2, 4, 8, and 12
Hospital Anxiety and Depression Scale (HADS)
Changes from baseline at weeks 1, 2, 4, 8, and 12
Time frame: weeks 1, 2, 4, 8, and 12
Quality of life (SF-36)
Changes from baseline at weeks 1, 2, 4, 8, and 12
Time frame: weeks 1, 2, 4, 8, and 12
Aural fullness scale (AFS)
Visual analog scale (0-10) changes from baseline at weeks 1, 2, 4, 8, and 12
Time frame: weeks 1, 2, 4, 8, and 12
Salvage treatment rate
Proportion of participants requiring intratympanic steroid injection due to insufficient hearing recovery at day 14
Time frame: day 14
Safety outcome
Proportion of adverse events in both groups at week 8
Time frame: week 8
Plan to share: Undecided
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Dec 2027, 20 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eye & ENT Hospital of Fudan University →